SCHEMBL427874

SCHEMBL427874

CN(C(=O)n1cnc(-c2ccc(O)cc2)c1)C1CCCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 2/20 0.64
▸ CES2 O00748 1/20 0.64
▸ USP19 O94966 1/20 0.41
▸ TRPV1 Q8NER1 2/20 0.39
▸ TRPA1 O75762 1/20 0.39
▸ MGLL Q99685 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ S1PR1 P21453 2/20 0.39
▸ FYN P06241 2/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ TYR P14679 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MAP3K11 Q16584 1/20 0.35
▸ MKNK1 Q9BUB5 1/20 0.35
▸ MKNK2 Q9HBH9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425914 0.99 FAAH (0.66) FAAHCES2USP19TRPV1TRPA1
SCHEMBL14950186 0.90 FAAH (0.64) FAAHCES2USP19TRPV1TRPA1
SCHEMBL427732 0.89 FAAH (0.53) FAAHCES2FYNNPC1RAB9A
SCHEMBL428013 0.89 FAAH (0.53) FAAHCES2FYNALDH1A1HPGD
SCHEMBL14950289 0.89 FAAH (0.66) FAAHCES2USP19TRPV1TRPA1
SCHEMBL427057 0.89 FAAH (0.63) FAAHCES2USP19TRPV1TRPA1
SCHEMBL427830 0.88 FAAH (0.66) FAAHCES2USP19TRPV1TRPA1
Bromide SCHEMBL16432654 0.88 FAAH (0.52) FAAHCES2FYNALDH1A1HPGD
SCHEMBL425807 0.88 FAAH (0.65) FAAHCES2USP19TRPV1TRPA1
SCHEMBL425056 0.88 FAAH (0.65) FAAHCES2USP19TRPV1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 — — US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 — — US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 — — US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 — — US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 — — US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885CES2 62/4885USP19 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback